Inovio is going after the 'impossible tumor' left in the dust of new cancer meds

Patients with difficult cancers have seen a massive influx of new treatment options and hope for prolonged survival in recent years—except for those with the aggressive brain cancer glioblastoma.

Inovio is hoping to change that with a new DNA medicine combination of INO-5401, INO-9012 and Regeneron-Sanofi’s PD-1 inhibitor Libtayo. The Plymouth Meeting, Pennsylvania-based biotech is conducting a phase 1 clinical trial called GBM-001 that will provide early data in a quest to extend the lives of newly-diagnosed patients beyond the three to five years that is currently the norm.